Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Capricor Therapeutics (CAPR) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Capricor Therapeutics (CAPR) over the last 17 years, with Q3 2025 value amounting to $19.5 million.

  • Capricor Therapeutics' Cash & Equivalents fell 7146.66% to $19.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.5 million, marking a year-over-year decrease of 7146.66%. This contributed to the annual value of $11.3 million for FY2024, which is 2319.08% down from last year.
  • As of Q3 2025, Capricor Therapeutics' Cash & Equivalents stood at $19.5 million, which was down 7146.66% from $23.2 million recorded in Q2 2025.
  • Over the past 5 years, Capricor Therapeutics' Cash & Equivalents peaked at $68.4 million during Q3 2024, and registered a low of $6.2 million during Q1 2024.
  • For the 5-year period, Capricor Therapeutics' Cash & Equivalents averaged around $24.2 million, with its median value being $16.4 million (2022).
  • As far as peak fluctuations go, Capricor Therapeutics' Cash & Equivalents tumbled by 8181.93% in 2023, and later soared by 66104.55% in 2024.
  • Over the past 5 years, Capricor Therapeutics' Cash & Equivalents (Quarter) stood at $34.9 million in 2021, then plummeted by 72.47% to $9.6 million in 2022, then soared by 53.02% to $14.7 million in 2023, then dropped by 23.19% to $11.3 million in 2024, then skyrocketed by 72.86% to $19.5 million in 2025.
  • Its last three reported values are $19.5 million in Q3 2025, $23.2 million for Q2 2025, and $28.8 million during Q1 2025.